Allena Pharmaceuticals, Inc. SG&A Expenses

SG&A Expenses of ALNA for past 10 years: annual, quarterly and twelve month trailing (TTM) including SG&A Expenses growth rates and interactive chart. Selling, general and administrative expense (SG&A) is reported on the income statement as the sum of all direct and indirect selling expenses and all general and administrative expenses (G&A) of a company. SG&A, also known as SGA, includes all the costs not directly tied to making a product or performing a service. That is, SG&A includes the costs to sell and deliver products and services and the costs to manage the company. It includes administrative


Highlights and Quick Summary

  • SG&A Expenses for the quarter ending March 31, 2022 was $3.8 Million (a 79.62% increase compared to previous quarter)
  • Year-over-year quarterly SG&A Expenses increased by 8.85%
  • Annual SG&A Expenses for 2021 was $12.7 Million (a 15.22% increase from previous year)
  • Annual SG&A Expenses for 2020 was $11 Million (a 13.7% increase from previous year)
  • Annual SG&A Expenses for 2019 was $9.68 Million (a 4.98% increase from previous year)
  • Twelve month SG&A Expenses ending March 31, 2022 was $12.7 Million (a 2.61% increase compared to previous quarter)
  • Twelve month trailing SG&A Expenses decreased by -0.15% year-over-year
Trailing SG&A Expenses for the last four month:
31 Mar '22 31 Dec '21 30 Sep '21 30 Jun '21
$12.7 Million $12.4 Million $13.1 Million $12.7 Million
Visit stockrow.com/ALNA for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical SG&A Expenses of Allena Pharmaceuticals, Inc.

Most recent SG&A Expensesof ALNA including historical data for past 10 years.

Interactive Chart of SG&A Expenses of Allena Pharmaceuticals, Inc.

Allena Pharmaceuticals, Inc. SG&A Expenses for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2022 $3.8
2021 $2.12 $3.32 $3.49 $3.48 $12.68
2020 $2.81 $2.97 $2.75 $2.88 $11.0
2019 $1.97 $2.53 $2.75 $2.43 $9.68
2018 $2.51 $2.39 $2.28 $2.04 $9.22
2017 $1.81 $1.41 $1.02 $1.19 $5.36
2016 $0.84 $4.08
2015 $2.37

Business Profile of Allena Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.